The switch/sucrose nonfermentable complex mutations (SWI/SNF‐mut) are common in non–small cell lung cancer (NSCLC). However, the association of SWI/SNF‐mut with the clinical outcomes of immune checkpoint inhibitors (ICIs), particularly of… Click to show full abstract
The switch/sucrose nonfermentable complex mutations (SWI/SNF‐mut) are common in non–small cell lung cancer (NSCLC). However, the association of SWI/SNF‐mut with the clinical outcomes of immune checkpoint inhibitors (ICIs), particularly of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs), has not been established.
               
Click one of the above tabs to view related content.